Prevention of coronary heart disease by raising high-density lipoprotein cholesterol?
- 1 December 2000
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 11 (6) , 627-637
- https://doi.org/10.1097/00041433-200012000-00010
Abstract
Consistent with several potentially anti-atherogenic activities of high-density lipoproteins in vitro, low plasma levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease. In addition to genes, lifestyle factors (e.g. smoking, being overweight and physical inactivity) strongly affect plasma high-density lipoprotein cholesterol levels. Moreover, a low level of high-density lipoprotein cholesterol interacts with other risk factors. Raising of high-density lipoprotein cholesterol by either adjustments of lifestyle or drug intervention as well as elimination of additional risk factors are thus thought to affect coronary risk. Here, we summarize the outcomes of observational and interventional studies as well as genetic and experimental research which have recently much advanced our understanding of the function and regulation of high-density lipoprotein metabolism. We conclude from the data that changes in the kinetics and functionality of high-density lipoprotein rather than changes in plasma high-density lipoprotein cholesterol levels per se will affect the anti-atherogenicity of therapeutic interference with high-density lipoprotein metabolism.Keywords
This publication has 110 references indexed in Scilit:
- Sterol-dependent Transactivation of theABC1 Promoter by the Liver X Receptor/Retinoid X ReceptorJournal of Biological Chemistry, 2000
- Low hepatic lipase activity is a risk factor for coronary artery diseaseAtherosclerosis, 2000
- Association of Cholesteryl Ester Transfer Protein– Taq IB Polymorphism With Variations in Lipoprotein Subclasses and Coronary Heart Disease RiskArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Transport of lipids from Golgi to plasma membrane is defective in Tangier disease patients and Abc1-deficient miceNature Genetics, 2000
- Hepatic lipaseCurrent Opinion in Lipidology, 1999
- Locally secreted apolipoprotein (APO) E inhibits vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cellsAtherosclerosis, 1999
- Molecular Cloning of the Human ATP-Binding Cassette Transporter 1 (hABC1): Evidence for Sterol-Dependent Regulation in MacrophagesBiochemical and Biophysical Research Communications, 1999
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.The American Journal of Cardiology, 1998
- High-Density Lipoprotein — The Clinical Implications of Recent StudiesNew England Journal of Medicine, 1989